The present invention relates to a solid oral preparation comprising the formula (3Z, 5S) ‑5‑ (hydroxymethyl) ‑1 ‑ [(2′‑methyl‑1,1′‑biphenyl‑4‑yl) carbonyl] pyrrolidine ‑3‑Keto‑O‑methyloxime compounds and / or their active metabolites, as well as those involved in the treatment and / or prevention of embryo implantation failure caused by underterm delivery, premature delivery, dysmenorrhea and uterine contractions use. The invention also relates to its preparation method.本發明涉及固體口服製劑，其包含式(3Z，5S)‑5‑(羥甲基)‑1‑[(2′‑甲基‑1，1′‑聯苯‑4‑基)羰基]吡咯烷‑3‑酮‑O‑甲基肟的化合物和／或其活性代謝物，以及涉及所述製劑在治療和／或預防未足月分娩、早産、痛經和子宮收縮導致的胚胎著床失敗中的用途。本發明還涉及其製備方法。
